Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X. Primary Sjögren syndrome. BMJ: British Medical Journal. 2012;344: e3821.
Leone MC, Alunno A, Cafaro G, Valentini V, Marcucci E, Bartoloni E, et al. The clinical spectrum of primary Sjögren’s syndrome: beyond exocrine glands. Reumatismo. 2017;69(3):93–100.
Article PubMed CAS Google Scholar
Mardale D-A, Opriș-Belinski D, Bojincă V, Bojincă M, Mazilu D, Păsăran E, et al. The physical and psychosocial impact of fatigue among patients with Sjögren’s syndrome: a systematic review. J Clin Med. 2024;13(6):1537.
Article PubMed PubMed Central CAS Google Scholar
Hackett KL, Davies K, Tarn J, Bragg R, Hargreaves B, Miyamoto S, et al. Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren’s syndrome. RMD Open. 2019;5(1): e000885.
Article PubMed PubMed Central Google Scholar
Meijer JM, Meiners PM, Huddleston Slater JJ, Spijkervet FK, Kallenberg CG, Vissink A, et al. Health-related quality of life, employment and disability in patients with Sjögren’s syndrome. Rheumatology (Oxford). 2009;48(9):1077–82.
Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med. 2004;164(12):1275–84.
Beydon M, McCoy S, Nguyen Y, Sumida T, Mariette X, Seror R. Epidemiology of Sjögren syndrome. Nat Rev Rheumatol. 2024;20(3):158–69.
Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, et al. Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(11):1983–9.
Article PubMed CAS Google Scholar
Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76(1):9–16.
Srivastava A, Makarenkova HP. Innate immunity and biological therapies for the treatment of Sjögren’s syndrome. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21239172.
Article PubMed PubMed Central Google Scholar
Chivasso C, Sarrand J, Perret J, Delporte C, Soyfoo MS. The involvement of innate and adaptive immunity in the initiation and perpetuation of Sjögren’s syndrome. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22020658.
Article PubMed PubMed Central Google Scholar
Scofield RH, Fayyaz A, Kurien BT, Koelsch KA. Prognostic value of Sjögren’s syndrome autoantibodies. J Lab Precis Med. 2018. https://doi.org/10.21037/jlpm.2018.08.05.
Article PubMed PubMed Central Google Scholar
Veenbergen S, Kozmar A, van Daele PLA, Schreurs MWJ. Autoantibodies in Sjögren’s syndrome and its classification criteria. J Transl Autoimmun. 2022;5: 100138.
Article PubMed CAS Google Scholar
Theander E, Jonsson R, Sjöström B, Brokstad K, Olsson P, Henriksson G. Prediction of Sjögren’s syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling. Arthritis Rheumatol. 2015;67(9):2427–36.
Article PubMed CAS Google Scholar
Brito-Zerón P, Acar-Denizli N, Ng WF, Zeher M, Rasmussen A, Mandl T, et al. How immunological profile drives clinical phenotype of primary Sjögren’s syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). Clin Exp Rheumatol. 2018;112(3):102–12.
Yazisiz V, Aslan B, Erbasan F, Uçar İ, Öğüt TS, Terzioğlu ME. Clinical and serological characteristics of seronegative primary Sjögren’s syndrome: a comparative study. Clin Rheumatol. 2021;40(1):221–9.
García-Carrasco M, Mendoza-Pinto C, Jiménez-Hernández C, Jiménez-Hernández M, Nava-Zavala A, Riebeling C. Serologic features of primary Sjögren’s syndrome: clinical and prognostic correlation. Int J Clin Rheumatol. 2012;7(6):651–9.
Mariette X. Sjögren syndrome: a forgotten or an overdiagnosed entity? J Rheumatol. 2024;51(1):10–2.
Stefanski AL, Tomiak C, Pleyer U, Dietrich T, Burmester GR, Dörner T. The diagnosis and treatment of Sjögren’s syndrome. Dtsch Arztebl Int. 2017;114(20):354–61.
PubMed PubMed Central Google Scholar
Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al. EULAR Sjögren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren’s syndrome. Ann Rheum Dis. 2010;69(6):1103–9.
Dumusc A, Ng WF, James K, Griffiths B, Price E, Pease C, et al. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren’s syndrome: examination of data from the UK Primary Sjögren’s Syndrome Registry. Swiss Med Wkly. 2018;148: w14588.
Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, et al. EULAR Sjögren’s syndrome patient-reported index (ESSPRI): development of a consensus patient index for primary Sjögren’s syndrome. Ann Rheum Dis. 2011;70(6):968–72.
Seror R, Bowman SJ, Brito-Zeron P, Theander E, Bootsma H, Tzioufas A, et al. EULAR Sjögren’s syndrome disease activity index (ESSDAI): a user guide. RMD Open. 2015;1(1): e000022.
Article PubMed PubMed Central Google Scholar
Seror R, Gottenberg JE, Devauchelle-Pensec V, Dubost JJ, Le Guern V, Hayem G, et al. European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index and European League Against Rheumatism Sjögren’s Syndrome Patient-Reported Index: a complete picture of primary Sjögren’s syndrome patients. Arthritis Care Res. 2013;65(8):1358–64.
Ture HY, Kim NR, Nam EJ. EULAR Sjögren’s syndrome patient-reported index (ESSPRI) and other patient-reported outcomes in the assessment of glandular dysfunction in primary Sjögren’s syndrome. Life (Basel). 2023. https://doi.org/10.3390/life13101991.
Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063–72.
Article PubMed CAS Google Scholar
Anderson P, Higgins V, Courcy Jd, Doslikova K, Davis VA, Karavali M, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on disease-specific programmes. Curr Med Res Opin. 2023;39(12):1707–15.
Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease-specific programme. BMJ Open. 2016;6(8): e010352.
Article PubMed PubMed Central CAS Google Scholar
Higgins V, Piercy J, Roughley A, Milligan G, Leith A, Siddall J, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371–80.
Article PubMed PubMed Central Google Scholar
Seror R, Meiners P, Baron G, Bootsma H, Bowman SJ, Vitali C, et al. Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. Ann Rheum Dis. 2016;75(11):1945–50.
Seror R, Bootsma H, Saraux A, Bowman SJ, Theander E, Brun JG, et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis. 2016;75(2):382–9.
Article PubMed CAS Google Scholar
Ture HY, Kim NR, Nam EJ. EULAR Sjögren’s syndrome patient-reported index (ESSPRI) and other patient-reported outcomes in the assessment of glandular dysfunction in primary Sjögren’s syndrome. Life. 2023;13(10):1991.
Comments (0)